Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
3
30%
Ph phase_2
4
40%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 32 (22.2%)

Trials by Status

terminated110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770
completedphase_3

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

NCT00492986
completedphase_2

BAY43-9006 Phase II Study for Renal Cell Carcinoma

NCT00661375
completedphase_2

Extension Program for Bay 43-9006

NCT00657254
completedphase_2

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

NCT00661180
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00692770Phase 3

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Completed
NCT00492986Phase 3

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Completed
NCT00661375Phase 2

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Completed
NCT00657254Phase 2

Extension Program for Bay 43-9006

Completed
NCT00661180Phase 2

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Completed
NCT00606125Phase 1

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Completed
NCT00562913Phase 1

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Completed
NCT01069328Phase 1

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Completed
NCT00110344Phase 2

Research Study for Patients With Metastatic Renal Cell Carcinoma

Terminated
NCT00895674

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10